New investors for Biomunex Pharmaceuticals

Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announced a capital increase and the investment from new shareholders in equity, actively supporting its growth trajectory and accelerating the development of its portfolio, particularly its MAIT engagers.

This transaction received support from the company's long-standing shareholders, including Biomunex's management team, as well as a group of new European and international investors. Eurobail, an operator specializing in commercial real estate, hospitality, and investment in innovative companies, is also acquiring a stake in the company.

Biomunex is the first company to develop a cancer immunotherapy approach that uses bispecific antibodies from its BiXAb platform to specifically target, engage, and redirect MAIT cells, a subpopulation of T cells naturally present throughout the body, particularly in mucosal tissues and barriers, to kill cancer cells for the treatment of solid tumors.